Loading
Inhibikase Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Sands Capital Life Sciences Pulse Fund II, L.P., was filed 24 Nov 2025.
Inhibikase Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Inhibikase Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 6 insiders have disclosed 6 filings since 21 October 2025.
Every open-market trade in the period is a purchase: 1 purchase worth €2.6M, from 1 insider, and not a single sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €2.6M, bought by Sands Capital Life Sciences Pulse Fund II, L.P. and made public on 24 November 2025.
Across the 5,456 companies tracked on its exchange, the median is 22 filings; at 6 filings, this issuer sits below that mark. Over the whole record (from 2020), the tally stands at 13 purchases and no sales.
The latest purchase dates back some time: it was published 334 days ago, on 24 November 2025. Typically, a trade is published a median of 3 days after it takes place. US insiders must file a Form 4 within two business days of a trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
24
Thresholds
n/a
Buy Volume
€5M
13 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleSands Capital Life Sciences Pulse Fund II, L.P.1 buy
Since the insiders bought
- +14.6%Entry US$1.57 · Close at T+90 US$1.80
- -38.9%Entry US$2.52 · Close at T+365 US$1.54
- -38.9%Entry US$2.52 · Close at T+365 US$1.54
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Inhibikase Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$5.55.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.63
Analyst consensus
10 analystsStrong buy
US$1.50Target US$5.55(+242%)US$8.00
Income statement
EBITDA-US$53.3M
Net income-US$48.3M0.0% margin
Valuation
PER (forward)-3.9x
P/Book1.9x
Beta0.90
Balance sheet & cash
Market capUS$226.7M
Free Cash Flow-US$28.2M
Profitability & ownership
ROE-52.0%
ROA-32.8%
% insiders6.1%
% institutions89.7%
Last declaration on 31 July 2026
Declarations24 total
18,030,000 sharesCommon StockSEC:0001231919-26-000815:0
21,854 shares@ US$1.260.0095% mcap100.0% of flowCommon StockSEC:0001193125-26-328467:0
255,299 shares0Common StockSEC:0001193125-26-068079:0
338,282 shares0Common StockSEC:0001193125-26-068077:0
19,089 shares0Common StockSEC:0001193125-26-068063:0
2,068,965 shares@ US$1.45100.0% of flowCommon StockSEC:0001875620-25-000025:0
Canonical exit: 19 Feb 2026 (T+90)
57,265 shares0Common StockSEC:0001193125-25-191463:0
1,460,000 shares@ US$1.37100.0% of flowCommon StockSEC:0000950170-24-116785:0
Canonical exit: 19 Jan 2025 (T+90)
145,000 shares@ US$1.37100.0% of flowCommon StockSEC:0000950170-24-116783:0
Canonical exit: 19 Jan 2025 (T+90)
365,000 shares@ US$1.37100.0% of flowCommon StockSEC:0000950170-24-116780:0
Canonical exit: 19 Jan 2025 (T+90)
5,000 shares@ US$0.802.9% of flowCommon StockSEC:0000899243-22-028794:0
Canonical exit: 14 Nov 2022 (T+90)
5,000 shares@ US$0.9763.4% of flowCommon StockSEC:0000899243-22-020094:0
Canonical exit: 25 Aug 2022 (T+90)
10,000 shares@ US$0.604.2% of flowCommon StockSEC:0000899243-22-019229:0
Canonical exit: 18 Aug 2022 (T+90)
3,948 shares@ US$0.644100.0% of flowCommon StockSEC:0000899243-22-019219:0
Canonical exit: 17 Aug 2022 (T+90)
21,853 shares@ US$2.0228.7% of flowCommon StockSEC:0001104659-22-001168:0
1,100 shares@ US$1.970.9% of flowCommon StockSEC:0001104659-21-141628:1
Canonical exit: 15 Feb 2022 (T+90)
3,186 shares@ US$1.962.6% of flowCommon StockSEC:0001104659-21-141628:2
Canonical exit: 15 Feb 2022 (T+90)
1,334 shares@ US$1.941.1% of flowCommon StockSEC:0001104659-21-141628:3
Canonical exit: 15 Feb 2022 (T+90)
400 shares@ US$1.930.3% of flowCommon StockSEC:0001104659-21-141628:4
Canonical exit: 15 Feb 2022 (T+90)
17,569 shares@ US$1.9822.7% of flowCommon StockSEC:0001104659-21-141628:0
Canonical exit: 15 Feb 2022 (T+90)
21,853 shares@ US$2.0227.9% of flowCommon StockSEC:0000899243-21-033598:0
16,918 shares@ US$4.5930.6% of flowCommon StockSEC:0000899243-21-019788:1
43,707 shares@ US$0.3810.2% of flowCommon StockSEC:0000899243-21-019788:0
44,143 shares@ US$10.0099.3% of flowCommon StockSEC:0001104659-20-140307:0
24 of 24 declarations
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. (ticker: IKT) is a U.S.-based biopharmaceutical company listed on the NASDAQ in the United States. It is best understood as a clinical-stage biotech story rather than a commercial pharmaceutical platform: the company’s value proposition depends primarily on the success of its pipeline, regulatory progress, and funding capacity. Founded in 2010 and publicly listed in December 2020, Inhibikase originally focused on neurodegenerative and related disorders, but in recent years it has increasingly emphasized cardiopulmonary disease, especially pulmonary arterial hypertension (PAH).
At the center of the company’s strategy is a kinase-inhibition platform. Inhibikase has historically worked on Abelson tyrosine kinase (c-Abl) biology, and more recently has positioned its lead development efforts around PAH pathways involving type III receptor tyrosine kinases, including platelet-derived growth factor receptors and c-Kit. Its lead program, IkT-001, is an imatinib-based prodrug/formulation being advanced for PAH with the aim of preserving potential efficacy while improving tolerability versus prior imatinib experiences in the indication. The company’s broader scientific approach remains focused on disease-modifying mechanisms, which is important because PAH is a severe and progressive disease with a high unmet medical need.
Read moreShow less
From a competitive standpoint, Inhibikase operates in a highly crowded and scientifically demanding biotech segment. It competes indirectly with specialty pulmonary hypertension companies, larger biopharma groups, and other rare-disease developers. Its differentiation lies in mechanism-driven development: the company is not simply pursuing incremental symptom management, but rather attempting to influence disease progression through targeted kinase inhibition. That can be attractive from an investor’s perspective, but it also creates significant binary risk, as clinical outcomes and regulatory interactions can materially re-rate the stock.
Geographically, the company is rooted in the United States, with a long-standing operational footprint tied to Atlanta, Georgia, and research/leadership activity also associated with Boston, Massachusetts. Historically, Inhibikase described itself as headquartered in Atlanta, and more recent company materials show a Delaware corporate presence with Boston-linked operations. Recent milestones include the February 2025 acquisition of CorHepta, expansion of the PAH leadership team, a large financing in 2025, and an April 2026 inducement grant announcement under NASDAQ listing rules. For investors, IKT is a small-cap U.S. NASDAQ biotech with a focused pipeline, a clear therapeutic thesis, and meaningful execution risk tied to clinical data readouts and capital markets access.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
